<DOC>
	<DOCNO>NCT01618513</DOCNO>
	<brief_summary>Treatment acromegaly somatostatin analog ( SA ) well-established primarily use insufficient surgical intervention , also primary medical treatment select patient . Evaluation treatment control base monitoring blood level growth hormone ( GH ) insulin-like growth factor-I ( IGF-I ) . However , evaluation disease control SA treatment always straightforward . It usually base normalization IGF-I achievement certain GH level . In approximately 40 % patient discordant value GH IGF-I level see treatment SA , normalize IGF-I level , despite elevate GH level . The mechanism behind observation unknown , indicate SA may affect difference . The primary objective study investigate disease control SA treatment best achieve monitoring either GH IGF-I .</brief_summary>
	<brief_title>Treatment Acromegaly With Somatostatin Analogs : GH vs. IGF-I Primary Biochemical Target</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Written inform consent Age &gt; 18 year Capable age Diagnosed acromegaly Sufficient treat least 6 month prior enrollment Pregnancy nursing Any disease may compromise ability comply protocol , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Somatostatin analog</keyword>
	<keyword>Treatment</keyword>
</DOC>